RENO, Nev., July 19, 2012 /PRNewswire/ -- Lifeline
Biotechnologies, Inc., (PINKSHEETS: LLBO) announces its primary
affiliate and investment, First Warning Systems, Inc., has updated
its website with a dynamic video. The video demonstrates the
Company's core technology that identifies breast tumors at the
earliest stage. Many of these tumors could develop into
threatening diseases. The early identification of these
tumors is many years ahead of other process capabilities (First
Warning's website, firstwarningsystems.com).
Jim Holmes, Lifeline's CEO said,
"This video is one of our best summaries of the First Warning
Systems' capabilities and explains how and when tumors occur and
how doubling times impact their development to a critical
stage. These tumors are breast tissue abnormalities, some of
which could develop into threatening diseases such as breast
cancers. We urge all to visit the First Warning website and
view this descriptive and informative video."
About Lifeline Biotechnologies Lifeline Biotechnologies,
Inc. (PINKSHEETS: LLBO) founded in 1994 is based in Reno, NV. The Company has licensed its primary
affiliate, First Warning Systems, Inc. The license covers
Lifeline's core, patented technology, and conveys the manufacturing
and marketing rights to First Warning. The device and process
identifies, at very early stages of development, breast tissue
abnormalities some of which are cancerous or pre-cancer.
Patents have been issued based on the results of three
clinical trials involving over 650 participants. The
developmental clinical trials confirmed the First Warning Systems'
"Proof of Concept," and its capabilities. www.lbti.com.
About First Warning Systems First Warning Systems (FWS)
founded in 2008, based in Reno, NV
is an affiliate of Lifeline Biotechnologies, Inc (LLBO). FWS
holds the exclusive development, marketing and manufacturing
license to commercialize LLBO's intellectual property for the FWS
product line. The product line is a device and process for
early detection of breast tissue abnormalities that provide the
opportunity to deal with health risk assessment and
management. Three clinical trials with over 650 participants
have achieved superior outcomes when compared to other
detection/diagnostic protocols. FWS is planning a final, limited
clinical trial followed by a FDA 510(k) device classification
submission. The 510(k) clears the FWS for
commercialization. www.firstwarningsystems.com.
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act
of 1933 and Section 27E of the Securities Act of 1934.
Statements contained in this release that are not historical
facts may be deemed to be forward looking statements. Investors are
cautioned that forward-looking statements are inherently uncertain.
Actual performance and results may differ materially from that
projected or suggested herein due to certain risks and
uncertainties including, without limitation, the ability to
obtaining financing, successful development of the Company's
product or market acceptance of the product and regulatory and
shareholder approval for anticipated actions.
For more information, contact: Jim
Holmes, CEO 775-852-3222 Email: lholmes@lbti.com
SOURCE Lifeline Biotechnologies, Inc.